Abstract:Clinical trials involving systemic neoadjuvant treatments in breast cancer aim to shrink tumors before surgery while simultaneously allowing for controlled evaluation of biomarkers, toxicity, and suppression of distant (occult) metastatic disease. Yet neoadjuvant clinical trials are rarely preceded by preclinical testing involving neoadjuvant treatment, surgery, and post-surgery monitoring of the disease. Here we used a mouse model of spontaneous metastasis occurring after surgical removal of orthotopically implanted primary tumors to develop a predictive mathematical model of neoadjuvant treatment response to sunitinib, a receptor tyrosine kinase inhibitor (RTKI). Treatment outcomes were used to validate a novel mathematical kinetics-pharmacodynamics model predictive of perioperative disease progression. Longitudinal measurements of presurgical primary tumor size and postsurgical metastatic burden were compiled using 128 mice receiving variable neoadjuvant treatment doses and schedules (released publicly at https://zenodo.org/records/10607753). A non-linear mixed-effects modeling approach quantified inter-animal variabilities in metastatic dynamics and survival, and machine-learning algorithms were applied to investigate the significance of several biomarkers at resection as predictors of individual kinetics. Biomarkers included circulating tumor- and immune-based cells (i.e., circulating tumor cells and myeloid-derived suppressor cells) as well as immunohistochemical tumor proteins (i.e., CD31 and Ki67). Our computational simulations show that neoadjuvant RTKI treatment inhibits primary tumor growth but has little efficacy in preventing (micro)-metastatic disease progression after surgery and treatment cessation. Machine learning algorithms that included support vector machines, random forests, and artificial neural networks, confirmed a lack of definitive biomarkers, which shows the value of preclinical modeling studies to identify potential failures that should be avoided clinically. Using simulations from a mechanistic mathematical model compared with preclinical data from surgical metastasis models, we found that anti-tumor effects of neoadjuvant receptor tyrosine kinase inhibitor treatment can differ between the primary tumor and metastases in the perioperative setting. Model simulations with variable drug doses and scheduling of neoadjuvant treatment revealed a contrasting impact on initial primary tumor debulking and metastatic outcomes long after treatment has stopped and the primary tumor has been surgically removed. Using machine-learning algorithms, we identified the limited power of several circulating cellular and molecular biomarkers in predicting metastatic outcomes, uncovering a potential fast-track strategy for assessing future clinical biomarkers by pairing patient studies with identical studies in mice.

A stochastic population pharmacodynamic model of QAP14 in the treatment of lung metastases of 4T1 breast cancer

Application of a count data model to evaluate the anti-metastatic efficacy of QAP14 in 4T1 breast cancer allografts

Disease Progression Model of 4T1 Metastatic Breast Cancer

Pharmacodynamic Model of Dopamine D1 Receptor Agonists in the Treatment of Breast Cancer Lung Metastasis

Characterization of Metastatic Tumor Formation by the Colony Size Distribution

Analyze Impact of Tumor-Associated Kinetics on Antibody Delivery in Solid Tumors with a Physiologically Based Pharmacokinetics/pharmacodynamics Model.

Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates

QAP14 Suppresses Breast Cancer Stemness and Metastasis Via Activation of Dopamine D1 Receptor

Machine-learning and mechanistic modeling of metastatic breast cancer after neoadjuvant treatment

Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities

Stochastic Evolution of Pancreatic Cancer Metastases During Logistic Clonal Expansion

Mathematical modeling and dynamic analysis for cancer resistance incorporating persister cells

Model-based Analysis for Investigating the Impact of Tumor Size, Lymphocyte and Neutrophil on the Survival of Breast Cancer 4 T1 Tumor-Bearing Mice

Mathematical Modeling of Tumor Growth in Preclinical Mouse Models with Applications in Biomarker Discovery and Drug Mechanism Studies

Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug Development

Radiation-Induced Pulmonary Injury Accelerated Pulmonary Metastasis in A Mouse Model of Breast Cancer

A Mathematical Model to Study the Effect of Drug Kinetics on the Drug-Induced Resistance in Tumor Growth Dynamics

Establishing the Nude Mice Bone Metastasis Model of Lung Adenocarcinoma and Applying MicroCT into the Observation

Inter-Metastatic Heterogeneity of Tumor Marker Expression and Microenvironment Architecture in a Preclinical Cancer Model

Pharmacokinetic-pharmacodynamic Modeling of the Antitumor Effect of TM208 and EGFR-TKI Resistance in Human Breast Cancer Xenograft Mice

Pharmacokinetic-pharmacodynamic Modeling of the Anticancer Effect of Erlotinib in a Human Non-Small Cell Lung Cancer Xenograft Mouse Model